SEC Form 4 · accession 0001123292-16-001535
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard T Kenney
Officer — Chief Medical Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 7:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jan 4, 2016 | A | 7,000 | $0.00 | A | 7,522 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $19.39 | Jan 4, 2016 | A | 30,000 | A | — | Jan 4, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
- F2One quarter of the total restricted stock units vest annually beginning January 4, 2017, subject to the Reporting Person's continuous service through each such date.
- F3Reflects the acquisition of 170 shares on June 30, 2015 and 352 shares on December 31, 2015 pursuant to the Immune Design Corp. 2014 Employee Stock Purchase Plan.
- F4One quarter of the shares underlying the option will vest on January 4, 2017, and the remainder of the shares underlying the option will vest at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date.